A Convergence of Histopathology and Genetics for Anticipating Chemotherapy Response in ovarian cancer.

Recent advancements in histopathology and genetics have enabled the development of personalized medicine approaches that can improve patient outcomes by tailoring treatments based on individualized genetic and clinical characteristics. In the field of oncology, chemotherapy is often used as a treatment option, but the efficacy of chemotherapy varies between patients due to differences in genetic makeup and tumor characteristics. Therefore, identifying predictive biomarkers of chemotherapy response is crucial for effective treatment planning. In this context, we integrate histopathology images with genetic features aimed at predicting chemotherapy response in ovarian cancer patients. Ultimately, the convergence of histopathology and genetics has the potential to transform cancer treatment by enabling the development of more personalized and effective treatment plans based on an individual patient's unique molecular profile.